Clinical Trial

Speech Treatment for Minimally Verbal Children With ASD and CAS

Study acronym: TxMVASD+CAS
Recruiting
View on ClinicalTrials.gov →
Summary
Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-09-22; most recent amendment 2026-03-25.
Status change: Not Yet Recruiting → Recruiting 2023-11-07
Trial Details
NCT Number NCT05066178
Lead Sponsor MGH Institute of Health Professions
Conditions Developmental Verbal Dyspraxia, Autism Spectrum Disorder
Enrollment 20 participants
Start Date 2024-05-01
Primary Completion 2030-04-30 (estimated)
Study Completion 2030-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-30